by Administrators Qynapse | Sep 8, 2021
QyScore® produces a wide range of automated neuroimaging biomarkers to assist physicians making clinical care decisions and monitoring patients over time. QyScore® is FDA-Cleared, CE-Marked and soon expanding into new global markets. QyScore® also has demonstrated...
by Administrators Qynapse | Sep 8, 2021
by Administrators Qynapse | Sep 8, 2021
Peace of Mind. The future of neuroimaging is here. Why Qynapse? Peace of Mind. Why Qynapse? The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we...
by Administrators Qynapse | Aug 26, 2021 | News
BOSTON, MA, July 26, 2021 /PRNewswire/ – QYNAPSE Inc., a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, is attending the Alzheimer’s Association International Conference 2021 (AAIC) on July 26-30, 2021 in...
by Administrators Qynapse | Jun 22, 2021
The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust. Patients Providers Payers Pharma...
